GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMC 3885345)

Published in Cancer Immunol Res on November 01, 2013

Authors

David A Schaer1, Sadna Budhu1, Cailian Liu1, Campbell Bryson2, Nicole Malandro3, Adam Cohen4, Hong Zhong1, Xia Yang1, Alan N Houghton1, Taha Merghoub1, Jedd D Wolchok5

Author Affiliations

1: Swim Across America & Ludwig Collaborative Lab Laboratory, Immunology Program, Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY.
2: Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, New York, NY.
3: Swim Across America & Ludwig Collaborative Lab Laboratory, Immunology Program, Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY ; Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, New York, NY.
4: Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA.
5: Swim Across America & Ludwig Collaborative Lab Laboratory, Immunology Program, Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY ; Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, New York, NY ; Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center, New York, NY.

Associated clinical trials:

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001) | NCT01239134

Articles citing this

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09

Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunother Cancer (2016) 1.41

Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17

Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16

Treg functional stability and its responsiveness to the microenvironment. Immunol Rev (2014) 1.01

Roles of regulatory T cells in cancer immunity. Int Immunol (2016) 0.95

Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells. J Immunol Res (2015) 0.89

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer (2014) 0.87

Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients. Arthritis Res Ther (2014) 0.83

Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity. Proc Natl Acad Sci U S A (2016) 0.82

Increased antigen presentation but impaired T cells priming after upregulation of interferon-beta induced by lipopolysaccharides is mediated by upregulation of B7H1 and GITRL. PLoS One (2014) 0.81

Anti-GITR therapy promotes immunity against malignant glioma in a murine model. Cancer Immunol Immunother (2016) 0.78

Immune based therapy for melanoma. Indian J Med Res (2016) 0.78

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res (2015) 0.78

The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight (2016) 0.78

Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J Immunol Res (2016) 0.77

Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. J Immunother Cancer (2015) 0.77

Ubiquitous points of control over regulatory T cells. J Mol Med (Berl) (2014) 0.76

Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation. J Immunol (2016) 0.76

Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76

Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol (2016) 0.75

The Ikaros family of zinc-finger proteins. Acta Pharm Sin B (2016) 0.75

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential. Oncoimmunology (2017) 0.75

Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Expert Opin Biol Ther (2016) 0.75

TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines. Curr Opin Immunol (2017) 0.75

Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4(+) T cells combined with agonist α-GITR mAb promotes durable CD8(+) T-cell-dependent antitumor immunity. Oncoimmunology (2017) 0.75

Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. Immunotherapy (2017) 0.75

Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy. J Immunother Cancer (2017) 0.75

Articles cited by this

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79

A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol (2005) 11.48

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol (2002) 9.18

Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65

Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med (2005) 7.87

Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol (2007) 6.80

Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity (2012) 4.98

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77

Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A (2009) 4.25

Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 3.40

Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity (2011) 3.40

Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol (2004) 3.15

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06

Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med (2012) 2.97

Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol (2011) 2.80

Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood (2006) 2.42

Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol (2011) 2.04

Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol (2004) 1.86

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One (2010) 1.69

A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol (2010) 1.65

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57

Phenotypic and functional properties of Helios+ regulatory T cells. PLoS One (2012) 1.52

CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med (2010) 1.48

Science gone translational: the OX40 agonist story. Immunol Rev (2011) 1.39

Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med (2012) 1.38

Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol (2006) 1.36

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med (2012) 1.32

Modulation of GITR for cancer immunotherapy. Curr Opin Immunol (2012) 1.17

T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev (2011) 1.17

Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother (2010) 1.16

A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol (1999) 1.12

CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol (2010) 1.08

Helios induces epigenetic silencing of IL2 gene expression in regulatory T cells. J Immunol (2012) 1.06

Modulation of Treg cells/T effector function by GITR signaling is context-dependent. Eur J Immunol (2013) 0.99

Stability of regulatory T-cell lineage. Adv Immunol (2011) 0.91

Loss of T regulatory cell suppression following signaling through glucocorticoid-induced tumor necrosis receptor (GITR) is dependent on c-Jun N-terminal kinase activation. J Biol Chem (2012) 0.90

Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. PLoS One (2011) 0.88